This inventor holds 61 USPTO granted patents, plus 4 CIPO patents and 1 EPO patent, primarily in Antibiotic Development (CPC class 536 ). Top assignees: Bristol-Myers Company, Bristol-Myers Squibb Compnay, Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai. Active years: 1976-2015.
Inventors with similar research interests:
Location History:
- Kamakura, JA (1976 - 1978)
- Kamakura, JP (1978 - 1980)
- Kamakurashi, JP (1979 - 1980)
- Kanagawaken, JP (1980)
- Sakae-ku, Yokohama, JP (1991)
- Yokohama, JP (1980 - 2013)
- Kanagawa, JP (1993 - 2015)
Company Filing History:
18 out of 637 
15 out of 3,735 
12 out of 212 
Years Active: 1976-2015
Areas of Expertise:
Title: The Innovations of Toshikazu Oki: Pioneering Nasal Pharmaceutical Compositions
Introduction: Toshikazu Oki, a prominent inventor based in Yokohama, Japan, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 61 patents. His innovative work primarily focuses on enhancing the effectiveness of nasal drug delivery systems, resulting in improved absorption efficiency for various pharmaceutical compounds.
Latest Patents: Among Toshikazu Oki's notable inventions are his latest patents related to compositions for nasal administration of pharmaceuticals. These compositions comprise a pharmaceutical, along with a physiologically active peptide or a peptide-related compound. The inclusion of crystalline cellulose with a specific particle diameter and partially pregelatinized starch serves as a carrier, leading to significantly enhanced in vivo absorption efficiency of the pharmaceuticals. The dual emphasis on both the formulation and the carrier system marks a noteworthy advancement in the field.
Career Highlights: Throughout his career, Toshikazu Oki has collaborated with esteemed companies, including Bristol-Myers Company and Bristol-Myers Squibb Company. His work at these organizations has allowed him to refine his inventions and push the boundaries of pharmaceutical innovation. Oki's dedication to research and development has established him as a leading figure in his domain.
Collaborations: Toshikazu Oki's journey has been enriched by collaborations with prominent peers in the industry. Notable among his coworkers are Hamao Umezawa and Masataka Konishi. Their collective expertise and insights have contributed to the successful development of cutting-edge pharmaceutical formulations.
Conclusion: With a robust collection of patents and a commitment to improving pharmaceutical delivery systems, Toshikazu Oki continues to influence the landscape of nasal drug administration. His innovations not only enhance the efficacy of treatments but also embody the spirit of progress in pharmaceutical sciences. As he continues his work, the potential for further breakthroughs remains vast.